Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Older men more likely than women to die after pneumonia

Older men more likely than women to die after pneumonia

April 30, 2009

Differing biological response to infection between men and women may explain higher death rates among older men who are hospitalized with community-acquired pneumonia (CAP). The findings, published online in the Critical Care Medicine journal, may have important implications for understanding sex differences in life expectancy.

"Our study found that men with CAP were less likely to survive after an infection compared to women and this was not explained by differences in demographics, health behavior, chronic health conditions or quality of care," said Sachin Yende, M.D., assistant professor in the Department of Critical Care Medicine at the University of Pittsburgh School of Medicine and corresponding author of the study.




The researchers measured blood levels of inflammatory indicators, including tumor necrosis factor (TNF) and interleukins 6 and 10, coagulation indicators including Factor IX, and fibrinolysis indicators including D-dimer concentrations. They found patterns in these biomarkers that suggest men generate a stronger inflammatory and coagulation response and, perhaps, break up blood clots more quickly than women in response to infection. "These differences in inflammatory, coagulation and fibrinolysis biomarkers among men may explain the reduced short-term and long-term survival," said Dr. Yende.

Data were gathered from the multicenter Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Participants were enrolled upon emergency department admission at 28 academic and community hospitals in Pennsylvania, Connecticut, Michigan and Tennessee from 2001 to 2003. The study included 2,320 subjects, with a mean age of 64.9 years, 1,136 of whom were men. The men were sicker on admission, more likely to be smokers, and had at least one chronic health condition, such as cardiac disease or cancer. Severe sepsis occurred in 588 (31 percent) subjects. Of these, about half had severe sepsis on their first day of hospitalization.

Men had a higher risk than women of death at 30 days (7 percent vs. 4.5 percent), 90 days (11.4 percent vs. 8.6 percent) and one year (21 percent vs. 16 percent). "Even compared to women with an equivalent illness severity, men were more likely to die," Dr. Yende noted. "Survival differences persist up to one year after the initial hospitalization, when most patients had recovered from the pneumonia and left the hospital."

"To our knowledge, this is the largest study comparing biological response to infection between men and women. Our results suggest that immune response to infection may be an important target for interventions to reduce sex disparities in the outcomes of infections," said senior author Derek C. Angus, M.D., professor and chair in the Department of Critical Care Medicine at the University of Pittsburgh School of Medicine and principal investigator of the study.

"More studies will be needed to determine why the biological response differs between men and women," said Dr. Yende. "A clearer understanding may be useful toward designing interventions specifically targeted to men or women."

The GenIMS researchers hope to identify whether certain changes in the genes for key inflammatory molecules are associated with the risk of developing pneumonia, and the risk of progression to severe sepsis, septic shock, organ dysfunction or death. Because pneumonia is the most common cause of sepsis, patients with this infection represent an excellent clinical model for studying sepsis in a relatively homogeneous population.

In a paper published online on April 3 in The FASEB Journal, GenIMS researchers led by Drs. Yende and Angus found that people with certain gene variations associated with higher levels of macrophage migration inhibitory factor, an innate immune response regulator, were less likely to die following CAP.

"Macrophage migration inhibitory factor is a molecule that plays an important role in inflammation and has been shown to worsen outcomes in animal models of sepsis. Our results are intriguing in light of these findings and as other research groups are trying to design human studies to block this molecule in sepsis," said Dr. Yende. In future work, the researchers will continue to examine relationships between sex and gene variations in CAP, sepsis and survival.

University of Pittsburgh Schools of the Health Sciences



Related Sepsis Current Events and Sepsis News Articles Sepsis Current Events and Sepsis News RSS Sepsis Current Events and Sepsis News RSS
A Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.

Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.

Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.

OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.

Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).

Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.

Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.

Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.

Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
Sepsis: New Strategies for Management

Sepsis: New Strategies for Management
by Jordi Rello (Editor), Marcos I. Restrepo (Editor)

Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of Sepsis: New Strategies is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract.



Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine)

Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine)
by Edward Abraham (Editor), Mervyn Singer (Editor)

There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis.

Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care

Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care
by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor)

Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies.

Deep Sea Creatures

Deep Sea Creatures
by Monstrum Sepsis
Monstrum Sepsis (Performer)

Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms.

Primordial Notions Delta 2001-2004

Primordial Notions Delta 2001-2004
Monstrum Sepsis (Primary Contributor)



  Bacteria Sepsis: Video 1 of 3 [VHS]
Starring: Diane Charsha



Management of Sepsis: the PIRO Approach

Management of Sepsis: the PIRO Approach
by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor)

Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe...

Sepsis (Competency-Based Critical Care)

Sepsis (Competency-Based Critical Care)
by Simon V. Baudouin (Editor)

Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The...

Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs)

Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs)
by Novartis

IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such...

Primordial Notions Gamma 1996-2000

Primordial Notions Gamma 1996-2000
Monstrum Sepsis (Primary Contributor)



© 2009 BrightSurf.com